• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of therapeutic agents for urinary incontinence by in vivo analysis of dru-receptor binding characteritics

Research Project

Project/Area Number 11672271
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field 応用薬理学・医療系薬学
Research InstitutionUniversity of Shizuoka

Principal Investigator

YAMADA Shizuo  Department of Biopharmacy, Shool of Pharmaceutical Sciences, University of Shizuoka, Associate Professor, 薬学部, 助教授 (80106434)

Project Period (FY) 1999 – 2000
Project Status Completed (Fiscal Year 2000)
Budget Amount *help
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 2000: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 1999: ¥1,600,000 (Direct Cost: ¥1,600,000)
KeywordsUrinary incontinence / Propiverine / Oxybutynin / Transdermal therapeutic sys em / Muscarinic receptors / Urinary bladder / submaxillary gland / Receptor binding / プロピベリン
Research Abstract

Anticholinergic agents such as propiverine and oxybutynin (Oxy) are widely used for the treatment of micturition and urge urinary incontinence. However, the use of these drugs is often limited by systemic side effects such as dry mouth known to occur frequently when they were orally administered, and also by short-duration of action. To develop effective agents in the therapy of DI, we characterized muscarinic receptor binding in rat tissues after the oral administration of propiverine and oxybutynin and after the transdermal application of Oxy (MM-801).
[Experiment I] : Oral administration of oxybutynin caused a significant increase in the apparent dissociation constant (K_d) for specific (-)-[^3H]QNB binding in the rat bladder, prostate, submaxillary gland, heart and cerebral cortex, compared with each of the control values. Also, in the submaxillary gland of these rats, there was a reduction in the maximal number of binding sites (B_<max>) for (-)-[^3H]QNB binding. Similarly, oral ad … More ministration of propiverine brought about a significant increase in the K_d values for (-)-[^3H] QNB binding in rat tissues including the bladder, and greater increase in K_d values was seen in the rat prostate, heart and submaxillary gland. On the other hand, oral administration of propiverine, unlike oxybutynin, resulted in very little reduction in the B_<max> valules for (-)-[^3H] QNB binding in the submaxillary gland. In conclusion, the present study has shown that oxybutynin and propiverine, after oral administration, bind significantly to muscarinic receptors in tissues such as the bladder and that oxybutynin appears to exhibit long-term binding to muscarinic receptors in the salivary gland.
[Experiment II] : Following the oral administration of Oxy, there was a significant increase in dissociation constant (K_d) for specific [N-methyl-^3H] scopolamine (NMS) binding in urinary bladder, submaxillary gland, heart and colon of rats compared with the value of control rats, and a concomitant reduction of maximal number of binding sites (B_<max>) only in submaxillary gland and heart. Such increase in K_d value in each tissue was seen at 1 and 3 hr after oral administration of Oxy, but not at 12 and 24 hr. In contrast, a significant reduction of B_<max> value in submaxillary gland and heart was maintained for at least 24 hr. Transdermal application of MM-801 for 2-48 hr caused a significant increase in K_d value for [^3H] NMS binding in bladder, submaxillary gland, heart and colon of rats, and there was little reduction of B_<max> value in each tissue. The increment of K_d value increased with the application time of MM-801, being maximal at 12 hr later. These data suggest that the transdermally administered Oxy (MM-801) binds significantly to the muscarinic receptor in urinary bladder of rats and the binding to the receptor in submaxillary gland is easily reversible by this TTS but not by the oral administration. The present study may provide a rationale for the usefulness of transdermal application of Oxy in the therapy of DI. Less

Report

(3 results)
  • 2000 Annual Research Report   Final Research Report Summary
  • 1999 Annual Research Report
  • Research Products

    (6 results)

All Other

All Publications (6 results)

  • [Publications] 隠岐知美,山田静雄 他: "尿失禁・頻尿治療薬、オキシブチニンの経皮吸収製剤のムスカリン性受容体結合動態"Progress in Drug Delivery System. IX. 51-60 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Oki,T.,Yamada,S.,Tohma,A.,Kimura,R.: "Muscarinic receptor binding characteristics in rat tissues after oral administration of oxybutynin and propiverine"Biol.Pharm.Bull.. (in press).

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Oki, T., Yamada, S., Tohma A.and Kimura, R.: "Muscarinic receptor binding characteristics in rat tissues after oral administration of oxybutynin and propiverine."Biol.Pharm.Bull. (in press).

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Oki, T., Yamada, S., Toma, A., Kimura, R., Kawashima, A.and Uchida, M.: "Muscarinic receptor binding of transdermally administered oxybutynin in treatment of detrusor instability."Prog.Drug Deliv.System. IX. 51-60 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] 隠岐知美,山田静雄 他: "尿失禁・頻尿治療薬、オキシブチニンの経皮吸収製剤のムスカリン性受容体結合動態"Progress in Drug Delivery System. IX. 51-60 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Oki,T.,Yamada,S.,Tohma,A.,Kimura,R.: "Muscarinic receptor binding characteristics in rat tissues after oral administration of oxybutynin and propiverine"Biol.Pharm.Bull.. (in press).

    • Related Report
      2000 Annual Research Report

URL: 

Published: 1999-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi